Top Banner
ST. LOUIS TO BOSTON OCTOBER 4-6, 2016
44

nineteen startups

Feb 14, 2017

Download

Documents

danglien
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: nineteen startups

ST. LOUIS TO BOSTONOCTOBER 4-6, 2016

Page 2: nineteen startups

2

ST. LOUIS FINANCIAL & INFORMATION SERVICES MARKET

St. Louis’ startup community has seen an explosion of new companies

launching and succeeding. St. Louis has an average of 6,500 new businesses

created each year in a wide range of industries including health and plant

sciences, software technology, financial services, and social entrepreneurship,

among others.

This new era of startups has been supported by a deep entrepreneurial

ecosystem including a growing cache of venture capital and private equity

funding that has hit record levels with more than $1 billion raised in the

last three years. Additionally, cost-effective real estate, unique accelerator

networks and expert mentoring services have been essential in the ecosystem’s

success. St. Louis was recently called by FiveThirtyEight as “the new startup

frontier” and the second fastest growing startup city in the country.

Led by our Accelerate St. Louis coalition and through a partnership with

Southwest Airlines, we’re traveling to Boston with some of the most dynamic

early stage companies, continuing to connect St. Louis’ startup ecosystem with

other vibrant regions as we have already done in San Francisco and New York.

Page 3: nineteen startups

3

PARTICIPATING ST. LOUIS STARTUPS

AirZaar, Ravi Sahu, Construction, Mining, Energy & Utilities........................................4

Applied Particle Technology, Jiaxi Fang, Hardware, IOT, CleanTech.............................6

EternoGen Aesthetics, LLC, Luis Jimenez, Aesthetic Dermatology, Plastic Surgery......8

FocalCast, Devin Turner, Enterprize Communications.................................................10

Greetabl, Joe Fischer, E-Commerce.............................................................................12

Immunophotonics, Lu Alleruzzo, Therapeutics, Immuno-Oncology...........................14

Kypha, Chad Stiening, Healthcare, Diagnostics...........................................................16

Leaguer, LLC, Carmen Bellavia, Sports Technology, SaaS............................................18

Lean Media, Inc., Beth Handrigan, Agriculture Advertising........................................20

NanoGuard Technologies, Mark Hochwalt, Postharvest Agriculture..........................22

Nanopore Diagnostics, Tom Cohen, Molecular Diagnostics, Biotechnology...............24

PFITR, Jim Koetting, Financial Software, Analytics......................................................26

Pro-Arc Diagnostics, Michelle Faits, Life Sciences, Diagnostics...................................28

Pulse Therapeutics, Sean Morris, Medical Device......................................................30

Ryvit, Tom Stemm, Technology, Software...................................................................32

SanusEO, Matt Fagin, Healthcare Services..................................................................34

Soozie’s Doozies, LLC, Olivia Kelvin, Consumer Products, Food & Beverage...............36

Sparo Labs, Abby Cohen, Healthcare, Digital Health..................................................38

Tunespeak, Tom Pernikoff, Music Technology.............................................................40

Page 4: nineteen startups

4

Value Proposition AirZaar is a Software platform for commercial drone operators and enterprise companies that rely on drone data. AirZaar helps manage and automate all drone data needs – from operations planning to aerial mapping intelligence - in one simple platform.

Business Description AirZaar provides commercial drone mission planning, compliance solutions & aerial data analytics from drone sensor data and images. Our turnkey solution maximizes drone services ROI for the commercial drone operators and enterprise customers enabling growth, revenue generation and cost reduction measures.

Core Technology/Products AirZaar is cloud based web platform that uses proprietary algorithms to automate the planning and aerial data collection process. AirZaar core technology uses machine learning and computer vision detection to build accurate measurements and analytics from drone images.

Market Opportunities Commercial drone industry is growing rapidly. According to FAA, the new Part 107 regulations could generate more than $82 billion for the U.S. economy and create more than 100,000 new jobs over the next 10 years. AirZaar is well positioned at the right time to streamline the drone usage problems for customers and reduce cost in their business operations.

Industry/Sector Construction, Mining, Energy & Utilities

Traction/Research Data AirZaar has 100+ beta users worldwide and have secured Letter of Intent for proof of concept from large Construction, Mining companies as well for Smart city initiatives project in India.

Competitive Advantage AirZaar is the first pre-flight and post-flight solution for the commercial drone industry in one place at industrial scale and its hardware agnostic.

Strategic Partners/Alliances AirZaar is partnered with top drone hardware company from China and have a reseller partner in Construction industry.

1920 McCausland Ave, St. Louis, MO 63117

Page 5: nineteen startups

[email protected] | www.airzaar.com

Current Investors AirZaar is self-funded so far.

Financials AirZaar is currently raising $500K on a convertible note to scale the sales and marketing.

Management Team Bios Ravi Sahu (CEO/Founder) has led large teams for fortune 500 companies globally to build and scale Enterprise Software products generating revenue up to $75M. He holds an MBA from Wash. U. Olin Business School. B.E. in Computer Science from top rated Indian university. He is also a fellow of the “Startup Leadership Program” & “Founders Network” based out of the Silicon Valley.

Ali Ahmadi (COO/ Co-Founder) Ali is a veteran of the U.S. Navy where he flew UAV/Drones with over 650+ successful flight missions. His background also includes managing UAV programs with the Department of Defense. Ali has over 12 yrs. of experience in the Energy/Utility industry managing project in nuclear, fossil & gas power plants in 17 different countries. Ali holds an MBA from Wash. U. Olin Business School & M.S./B.S. of Aerospace Engineering from Embry-Riddle Aeronautical University.

Kshitij Sharma (CTO) Founding member of Aruba Networks India (exit to HP~ $5B). Built engineering team of 500+ at CISCO. BTech from Indian Institute of Technology, Mumbai

Page 6: nineteen startups

6

Value Proposition APT is developing the world’s first intelligent air sterilization system for HVAC systems and hospitals. APT’s technology enables better indoor air quality in high flow systems such as HVAC systems by removing odors and destroying airborne pathogens while reducing HVAC energy consumption by up to 30%. Compared to HEPA filter systems, APT’s system is easier to use, has a significantly lower life cycle cost, and better performance leading to a 2-year payback.

Business Description APT will sell intelligent air sterilization units along with integrated air quality sensors. This will be a hardware enabled service model where we charge $20,000 per air handling unit, with 10-15% annual recurring revenue in indoor air quality monitoring and control services.

Core Technology / Products APT’s patented technology is based around a one-step photoionizer coupled electric field to charge and capture pollutants. This system can provide high particle collection efficiency, complete pathogen inactivation, and odor removal in a single system with negligible pressure drop leading to better air quality and a lower energy bill.

Market Opportunities The global air filtration market segments that could serve as future target markets for APT are valued at approximately $38 billion. APT would enter the market via a beach-head market of the hospital HVAC sector. The first entry into this sector will be through HVAC air purification retrofits which is a $450 M annual market.

Management Team Jiaxi Fang, PhD, CEO, Tandeep Chadha, PhD, (CTO), and Pratim Biswas, PhD, (CSO)

Industry/Sector Hardware, IOT, CleanTech

Current investors APT currently has no outside investors, and is currently funded through grants.

Traction / Research Data Awarded NSF STTR Phase I Grant, exclusive license secured, winner of the 2015 Global Impact Award and Arch Grants, recipient of the CleanTech Open Midwest 2015 Breakthrough Technology of the Year Award, MIT Clean Energy Prize, Partnership with hospitals for a test case.

4320 Forest Park Avenue, Suite 304, St. Louis, MO 63108

Page 7: nineteen startups

[email protected] | www.appliedparticletechnology.com

Competition / Competitive Advantage Patented technology

Strategic Partners / Alliances 8760 Engineering, Mercy Health

Management/Name Title Jiaxi Fang (CEO) Jiaxi received his PhD in Energy, Environmental and Chemical Engineering from Washington University in St. Louis studying nucleation and particle formation. During his PhD, Jiaxi also worked on management consulting projects while serving on the Board of Directors for the BALSA Group. Jiaxi received his B.S., M.S. Biological and Agricultural Engineering, University of California Davis

Tandeep Chadha (CTO) Tandeep received his PhD in the Department of Energy, Environmental and Chemical Engineering at Washington University in St. Louis developing synthesis techniques for new battery materials. Tandeep also holds his B. Tech. in Biotechnology from SASTRA University in India

Pratim Biswas (CSO) Professor Biswas is the inventor of the technology and an international recognized leader in Aerosol Science and Technology with over 250 peer reviewed publications. He serves as the chair of the Department of Energy, Environmental and Chemical Engineering at Washington University in St Louis.

Financials APT has raised $330,000 in non-dilutive funding for the development of a field prototype and is currently in the process of raising a seed round which will be used for building a minimum viable business product. APT has a target date of initial sales in 18 months.

Page 8: nineteen startups

81601 S Providence Rd, Columbia, MO 65211

Value Proposition EternoGen Aesthetics unites academic integrity with commercial excellence to innovate, expand and lead a new category of care: Bio-Dermal RestorationTM that addresses the unmet need for a more natural injectable filler product that can replace lost skin tissue for the Dermatology and Plastic Surgery industry.

Business Description EternoGen Aesthetics is a Medical Device company that has developed a transformative pipeline of first-in-class liquid collagen tissue products to deliver Bio Dermal Restoration, and has submitted a European CE clinical file for target approval in Q3 2017 and projected US approval in 2021.

Core Technology/Products Rapidly Polymerizing Collagen (RPC) aka “Liquid Tissue in a Syringe” will be the only Collagen that solves prior technical challenges and the only Dermal Filler that integrates into the skin to replace lost Collagen.

Market Opportunities The addressable market is the $2Billion injectable medical aesthetic, cash-pay market which is growing rapidly (CAGR 10%), none of the

current market options directly affect the underlying mechanism of skin ageing

Industry/Sector EternoGen’s primary targets are aesthetic dermatologists, ocular plastic surgeons, facial plastic surgeons and plastic surgeons in high-value markets initially in Europe and Asia and thereafter in the US. These doctors utilize dermal fillers to treat individuals (mostly females) striving to improve their appearance through correction of signs of aging such as lip augmentation, perioral and periorbital lines and wrinkles, and nasolabial folds.

Traction/Research Data Pre-clinical, and CE clinical study has proven safety and efficacy

Marketing research with KOLS has confirmed the need for a safe and lasting collagen

Expert collagen CMO contracted and successful production of engineering batches

Pre-launch program initiated with strong podium presence at major congresses from recognized clinical leaders

Leading European and Asian distributors recruited

Page 9: nineteen startups

[email protected] | www.eternogen.com

Competitive Advantage Easy to inject, rapidly solidifies upon contact with tissue

Non-inflammation of injection site

Looks and feels natural by restoring tissue, unlike current Fillers

Strategic Partners/Alliances EternoGen has secured a strategic partner during previous investment rounds.

Current Investors Missouri Technology Corporation

Centennial Investors

Angel investors, including physicians and subject matter experts

Financials Raised $8M from 2012 to 2016. Currently raising $8M Series A ($3M currently being raised through convertible notes) Target to reach $100M 5 years after CE Mark Approval.

Management Team Bios The marketing team members have led the dev. & launch of the current market leading dermal fillers RESTYLANE and JUVEDERM ULTRA & branding for BOTOX, & are closely networked in the industry.

Luis Jimenez, President & COO Luis is experience in technology transfers, commercialization of medical devices and quality. He worked in Operations for J&J, Quality for Biotech Pharmacal and IT Program

Management for Express Scripts. He has a Chemical Engineering and MBA, both with honors. His diverse background provides Luis with a unique insight into the medical device industry.

Anna Tenstam, Chairman and CEO Anna is an experience executive with multiple year managing clinical trials and sales organizations. She has over 30 years of experience in the aesthetic market where she participated in the launch of Restylane, Evolence and Aquamid. Anna managed the exit of Evolence, a cross-linked collagen to J&J for $160M in 2006.

Charles Weatherstone, CCO Charles is an expert in marketing and branding. As the Dir of Marketing for EMEA for Allergan he developed the branding and marketing for the number 1 filler in the world Juvederm Ultra.

Dale Devore, CSO Dale is an expert in commercialization and development of biomaterials. He founded the Collageneis and has been the FDA panel expert for major products in the us such as Sculptra, Radiesse among others. Dale has invented and commercialized numerous collagen products including a portfolio of over 70 patents.

Page 10: nineteen startups

10

Value Proposition Digital collaboration is increasing at an incredible rate and current enterprise technology is not interactive or interoperable, leaving organizations without an effective way to collaborate between their devices. FocalCast instantly turns any device into an interactive interface that anyone can join via smartphones, tablets, touch screens & PC’s. This enables users to share and annotate together on documents and whiteboards from any device creating effortless communication and giving new capabilities to existing technology. As a cloud-based platform, FocalCast is an infinitely scalable natural addition to existing audio and video conferencing enabling any organization to increase productivity and achieve more value from their current technology.

Business Description Founded by students at Marquette University, FocalCast was based on the emergence of new cloud technology and created out of their own need for an easy way to connect different devices. Our mission is to enable effortless communication and collaboration around the world by removing the barriers it takes to connect different types of technology and enabling educators

and professionals to get the most out of their technology. We have solidified our go-to-market strategy by integrating our platform directly with our partners software and structuring revenue-share agreements for them to sell our platform to their current customers. After going from 0 to $50,000 recurring revenue last month, we are preparing an international press release and co-webinars to launch the integrations in the European market.

Core Technology / Products FocalCast is a secure cloud-based collaboration platform that can be accessed from any internet-connected device with no downloads or plugins required.

Market Opportunities FocalCast is entering the $3.5 billion enterprise collaboration market through global parnterships with established technology providers. Integrating directly with complementary solutions enables us immediate access to the customers who need our technology most.

Industry/Sector Enterprise Communications

Current Investors Capital Innovators, St. Louis Arch Angels, Missouri Technology Corporation, Arch Grants

911 Washington Ave., Suite 739, St. Louis, MO 63101

Page 11: nineteen startups

[email protected] | www.focalcastapp.com

Traction / Research Data We recently went from 0 to $50,000 ARR and are on track to end with $200K ARR in 2016

Competitive Advantage Proprietary technology, Patent issued & patents pending, exclusive partnership agreements with industry leaders

Strategic Partners / Alliances FocalCast is a technology partner of Wacom, Qumu, SHARP and Pexip

Management Devin Turner An entrepreneur from an early age, Devin has worked for NASA, Gulfstream and other aerospace companies in both business and engineering roles to develop the skills to effectively launch a global business. As co-founder and CEO at FocalCast Devin manages business development, sales, design, operations, partnerships and investor relations.

Charlie Beckwith As a computer engineering graduate from Marquette University Charlie has a strong background in software development and methodology with a specialization in web-based applications. He has created the framework for the FocalCast Platform from scratch which has been used by thousands of professionals in over 130 countries around the world. Charlie is responsible for the development and testing of the FocalCast platform as well as the integrations with partner platforms.

Financials To date FocalCast has raised $500,000 in Seed funding and is currently considering additional investments.

Page 12: nineteen startups

12911 Washington Avenue, Ste 656, St. Louis, MO 63101

Value Proposition Greetabl is solving the Gifting Gap™. Those occasions when a greeting card isn’t enough, but spending a lot of time or money doesn’t make sense. It needs to be personal, but also convenient and in the $15-$30 range.

Business Description Greetabl is a fast-growing e-commerce company that sends beautiful, personalized greetings for when a card is not enough. Our patented greeting card doubles as a gift box. Users add their own photos and message along with a small gift, and we send it directly to the recipient.

Core Technology/Products Our technology and vision bridges the physical and digital worlds seamlessly and with a fresh brand relevancy. Today, we send photo-customized greetings in a few clicks. Tomorrow, we tackle all aspects of our users gifting needs to help her be a better friend.

Market Opportunities The gifts and greetings space is a $138 billion opportunity, and is undergoing a rapid shift to online purchases driven by the demand for convenience and customization creating enormous opportunities for digital first brands.

Industry/Sector E-commerce

Traction/Research Data Since our October 2015 launch we have served over 10,000 customers and are growing revenue at a +20% CMGR.

Competitive Advantage We are first-movers with a novel, patented product, a differentiated brand and business model, and a laser focus on a premium but accessible segment of the market in which we have identified a strong need and few good solutions.

Strategic Partners/Alliances RR Donnelley, Capital Innovators Tech Accelerator, Arch Grants, T-REx Incubator

Current Investors Lindbergh Technology Fund, Missouri Technology Corporation, Billiken Angel Network, PinPoint Capital.

Financials Greetabl oversubscribed its $750K Series Seed round and is planning its Series A financing.

Page 13: nineteen startups

[email protected] | greetabl.com

Management Team Bios Joe Fischer CFA helped found Soho House Mumbai, with a $13M raise and held significant financial and operational roles. He was previously Vice President in Global Investment Research at Goldman Sachs.

Zoe Scharf Received her BFA in Communication Design at Washington University in St. Louis. Before Greetabl, she consulted on branding for startups, and worked on large brand strategies as a designer at XPLANE.

Page 14: nineteen startups

14

Business Description Immunophotonics is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine (inCVAX) for the potential treatment of solid, metastatic tumors. While additional clinical trials are necessary to further assess safety and efficacy, first-in-human results of inCVAX have been encouraging.

Value Proposition Immunophotonics is pioneering a novel cancer immunotherapy with its proprietary drug (GC, N-dihydro-galacto-chitosan) that has shown promising results in first-in-human studies internationally. Extensive nonclinical research is being performed to enable submission of IND (US) and CTA (Europe) applications. In parallel, a randomized controlled trial on advanced breast cancer is being conducted in South America in partnership with a local pharma company (open IND, trial initiated Q3’16).

Core Technology / Products inCVAX belongs to a new class of therapeutic interventions that utilize intratumoral injections intended to elicit a systemic anti-tumor immune response against a cancer. The inCVAX two-step procedure involves: 1) priming a tumor with laser energy to

liberate an array of tumor antigens from whole cells, followed by 2) administration of GC, a proprietary semi-synthetic carbohydrate polymer designed to activate antigen-presenting cells and facilitate the uptake of tumor antigens, which in turn is intended to trigger a systemic anti-tumor immune response.

Market Opportunities Immuno-oncology represents the most promising research and therapeutic advances in cancer in the last 30 years. It uses the patient’s own immune system to detect and destroy cancer cells. In 2014 alone, immune-oncology drugs generated about $41B, an estimated 50% market share.

Management Team Bobby Sandage, Jr., PhD, Board Chairman >30 years of industry experience including executive VP and CSO at Indevus Pharmaceuticals, executive VP at Endo Pharmaceuticals, VP at Covidien and President & CEO of Coronado Biosciences.

Tomas Hode, PhD, CEO & Co-Founder >10 years’ experience in the life sciences industry including CEO of Irradia AB and researcher at Portland State University.

4320 Forest Park Ave, Suite 303, St. Louis, MO 63108

Page 15: nineteen startups

[email protected] | www.immunophotonics.com

Lu Alleruzzo, MBA, COO & Co-Founder Bioengineer with >6 years of industry experience, prior experience includes researcher at the University of Missouri and employment in the healthcare sector. Current Chairman for St. Louis American Cancer Society Leadership Council.

Joseph Raker, PhD, Chief Drug Development Officer Organic chemist with >13 years of pharmaceutical development experience including director at Kinentia Biosciences and Senior Manager at AMRI Burlington.

Industry/Sector Therapeutics, Immuno-oncology

Current Investors & Traction Immunophotonics has secured greater than $6M in equity financing, including investments from the following: Cultivation Capital, BioGenerator, iSelect, Centennial Investors, St. Louis Arch Angels, Angels Billiken Angels, family offices.

Strategic Partners / Alliances Immunophotonics has partnered with a South American company to further expand on previously conducted first-in-human studies on advanced breast cancer. Peruvian regulatory authorities have opened an IND in which up to 246 patients may be enrolled in the phase II/III pivotal study. In return for local rights in Peru, our Partner will provide local sponsor support and limited co-financing. Immunophotonics will receive a double digit royalty on

net sales with annual minimums. Expected trial completion is in 2019, followed by an NDA submission and commercialization. Market access in Peru may enable NDA applications in other Pacific Alliance countries.

Competitive Advantage inCVAX is an in situ autologous cancer vaccine that uses whole tumor cells from each individual patient as the source of tumor antigens without ex vivo preparations or pre-selection of tumor antigens. In a first-in-human clinical trial, several patients experienced shrinkage of both local tumors and distant metastases. In some cases, this led to a complete, long-term response.

Page 16: nineteen startups

16

Value Proposition Earlier detection of disease activity, earlier and more accurate treatment optimization, for patients with autoimmune and inflammatory disease

Business Description Kypha, Inc. (est. 2010) is a medical diagnostics company developing novel, FDA-cleared blood tests, including Complement tests, for clinical lab and point-of-care testing in autoimmunity and inflammation.

Core Technology/Products Comp act® lateral flow assay platform including multiple Complement tests and versatile reader. Product offering and IP also covers sample collection and stabilization reagents and methods for clinical Complement assessment.

Market Opportunities Lead markets are Rheumatology (autoimmune) and Nephrology (kidney) – clinical lab and point-of-care / physician office. Broad potential clinical utility of complement diagnostics is well-supported by historical studies in a wide range of other indications, including infection (sepsis), trauma and critical care, and cancer.

Industry/Sector Healthcare / Diagnostics

Traction/Research Data Product development of reader and first 2 tests completed and transferred to OEMs; Phase I of lead clinical study complete in SLE/lupus; Regulatory strategy informed via 3 pre-submissions and FDA feedback; Installed initial customer base and early adopters; CPT code and reimbursement already in place; US and international patents issued, several more pending.

Competitive Advantage Novel content and first-to-market Complement tests; Versatile platform supports clinical lab and POC testing; With FDA clearance, Kypha would have the first FDA-cleared Complement activation split product test on the market; Dominant IP position for clinical assessment and point-of-care measurement of Complement activation.

Strategic Partners/Alliances Axxin (OEM), IPOC (OEM), Quidel (Supply), Bethesda Group (Advisory)

4320 Forest Park Ave, Suite 304, St. Louis, MO 63108

Page 17: nineteen startups

[email protected] | www.kypha.net

Current Investors Arsenal Capital Management (lead), Regional funds (e.g., BioGenerator, MTC, Serra Ventures), Angel investors (e.g., Arch Angels, Billiken Angels)

Financials $12 MM total funding to date ($2 MM non-dilutive). Convertible Note bridge financing currently open

Management Team Bios Chad Stiening, PhD, CEO & Founder 2013 Missouri Entrepreneur of the Year. Founder and Partner, Common Place Holdings (early-stage bioscience investment fund).

Paul Olson, PhD, Founder & SAB Chair Harvard, Merck, Co-Founder and CSO at Potentia Pharma (acquired 2009 by Alcon), CSO at Open Cell Technology.

Nick Staten, Dir R&D 30-year industry veteran (Monsanto/Searle, Pfizer), prior IVD start-up Founder.

Martin Schmidt, PhD, Dir Clinical Dev Johns Hopkins, Vanderbilt, Washington Univ (STL)

Paul Bennett, Dir Ops and QA/RA 12 years in Prod Dev, Project Mgmt, Regulatory and QA at Bausch & Lomb (surgical instruments and devices)

Legal IP: Choate Hall & Stewart (Boston) – Brenda Jarrell

Regulatory: Morgan Lewis (D.C.) – Phoebe Mounts

Corporate: Polsinelli (St. Louis) – Andy Hoyne

Page 18: nineteen startups

18

Value Proposition Leaguer is a comprehensive web and mobile e-commerce platform that seamlessly orchestrates the most complicated organizational and operational aspects of youth and recreational sports. Leaguer enables league managers, coaches, parents, players – even referees! to execute previously disjointed activities such as ordering uniforms and spirit wear, scheduling practice facilities and personnel, collecting registration fees, and submitting player release forms, all in one place. Knowing that communication is critical in this environment, Leaguer provides and easy-to-use solutions for email and text messages as well as one-click social media publishing capabilities. No more cumbersome group texts, email blasts, rainout numbers to call, or phone chains!

Business Description Leaguer provides configurable websites for teams, clubs, and leagues that facilitates interaction with their players and participants. The business is structured to collect a 2% fee on all transactions run through the system. This includes registrations, dues, tournament and travel fees, and merchandise ranging from required gear to spirit wear for the whole family.

Core Technology / Products The web application and API are built on Ruby on Rails and the mobile app is built on the Ionic.js platform. The Leaguer infrastructure can scale to handle hundreds of millions of dollars in transactions. It is integrated with multiple payment solutions and allows customers to pay with credit card or PayPal.

Market Opportunities There are over 100 million players and parents involved in recreational sports and while there are several league management software solutions, there is no dominant player in the space. When coupled with the fact that less than 50% of youth sports organizations use a platform, Leaguer recognizes that a huge opportunity exists. Further, our exclusive agreement with USA Softball to provide league management software to their 2.4 million players translates to a $74MM per year revenue opportunity on its own.

Management Team Carmen Bellavia, CEO and Brandon Janosky, COO

Industry/Sector Sports Technology/SaaS

Current investors Stadia Ventures

Page 19: nineteen startups

[email protected] | www.leaguer.com

Traction / Research Data Leaguer experienced 2x revenue growth in 2014 and 2015, is on pace for another strong year, and over 100 customer created websites this year.

Competitive Advantage Leaguer is well positioned to grab our share of a “hot” market. Specifically, the softball market. The platform compares favorably to competitors in features and functionality. It is the most comprehensive web and mobile solution on the market.

Strategic Partners / Alliances Leaguer is the official league management and website provider of USA Softball. JohnnyMacs Sporting Goods offers integrated fulfillment of sporting goods, uniform and team apparel orders. Other partnerships with RookiesApp (custom player cards), Meridix (streaming video) are currently being negotiated to provide a sales channel for those applications and new revenue opportunities for Leaguer.

Engagement with Stadia Ventures Accelerator also provides Leaguer with access to some of the major components of a successful business; entrepreneurs to fuel creative use of technology, investors to supply capital and offer feedback, and industry executives eager to explore new business and leverage their networks.

Management Carmen Bellavia, CEO Carmen has over 20 years experience building web and mobile applications. He has started 4 companies – three

are still in business – and was the first hire at a dotcom. Carmen is a McKinsey Alum who was brought back as a consultant several times to build custom applications deployed across the globe. Carmen gained his e-commerce expertise at a B2B retailer where he served as interim CTO and rebuilt the company’s entire technology infrastructure which facilitated growth from $25M to $70M in revenue. Carmen is a graduate of MIT with a degree in Electrical Engineering where he was a varsity volleyball player.

Brandon Janosky Brandon’s various roles as a partner at Detalus include coordinating the firm’s institutional business development efforts, and focusing on consulting for technology companies in the financial services and sports industries. He recently celebrated his 10 year anniversary with Detalus. A graduate of Villanova University, Brandon previously worked as an engineer in Washington Group International’s Power Division designing and analyzing emission reduction components. Brandon holds Series 7 and 66 licenses from FINRA.

Financials Leaguer is currently raising a seed round of $500,000 to accelerate the on boarding of USA Softball affiliates.

Page 20: nineteen startups

2010 Strecker Road, Suite 1100, Ellisville, MO 63011

Value Proposition Lean Media, Inc. connects agribusiness brands, farmers and other niche agriculture audiences through online advertising.

Business Description When it comes to buying online advertising, agribusiness companies currently have only two main options: buy directly from a handful of ag-focused websites with limited inventory and unsophisticated targeting, or rely on vague consumer-centric behavioral attributes from non-ag focused programmatic media companies with little to no knowledge of who that audience represents. Because of this, ag brands often unintentionally deliver a portion of their ads to the wrong audience segments. To solve this problem Lean Media is building the first ad platform dedicated to connecting agribusiness brands, farmers and other niche agriculture audiences online.

Core Technology/Products Lean Media’s platform is currently powered by semi-exclusive data sets and utilizes cutting edge data activation technologies to map physical addresses of verified ag audiences (such as farmers of specific crops, acreage or livestock) to IP

addresses and/or devices (desktop computers, laptops, tablets, etc.) and programmatically deliver ads directly to these audiences across the Internet on the websites they visit everyday. As a result, agribusiness advertisers can reach their target audiences across multiple devices with greater frequency and control - and with less competition from competing brands. Within the next year, Lean Media plans to develop a proprietary data set, which will serve as the foundation for fully automated campaign development, delivery and optimization with advanced measurement and analytics functionality.

Market Opportunities US agribusiness online programmatic media spend is estimated at $1B, a figure that grows significantly with expansion into the global agriculture market, with over 570 million farmers.

Management Team Beth Handrigan, CEO and Matt Jeter, COO

Industry/Sector Agriculture / Advertising

Current Investors Prosper Startup Accelerator, LLC

Page 21: nineteen startups

[email protected] | www.lean-media.com

Traction/Research Lean Media has generated extremely positive market interest/validation of need with both advertisers, and the agencies that represent them, resulting in achieving operating profitability and an ARR of $650K working with agencies for top tier clients such as John Deere, Syngenta, Dupont Pioneer, Farm Credit Services and Monsanto. These sales have been generated and supported by just three employees.

Competitive Advantage Lean Media is the first programmatic media company focused on serving the agribusiness vertical.

Strategic Partners/Alliances Lean Media is currently in the process of developing a channel partner strategy to scale sales efforts more quickly and maximize potential revenue.

Management Beth Handrigan Beth has over 15 years experience in B2B and B2C marketing and relies on her sharp, intuitive skills, relentless pursuit of knowledge, and commitment to process to provide the focused strategic input needed for highly effective campaign

development and execution. Beth’s diverse background includes owning her own consulting firm, working for industry leaders such as Microsoft and WellPoint, as well as serving as a Director at a national educational software company.

Matt Jeter Matt’s background involves a wide range of disciplines in fine art, digital media, online marketing and business development. He has over a decade of experience in digital media, online marketing and graphic design and was also the co-founder of Tower29 Marketing Group. Uniting the principles of smart design, creative technology and thoughtful execution, Matt has an innate ability to bridge the gap between form and function resulting in successful creative web-centric marketing solutions.

Financials Lean Media does not publicly disclose financial information. Lean Media is currently considering a Seed raise of $750K to support the ramp up of our existing operations and development of proprietary data sets.

Page 22: nineteen startups

22

Value Propostition 25% of the worlds grain is lost annually in the post-harvest supply chain due to spoilage and mycotoxin contamination. NanoGuard is advancing technology that significantly reduces these losses, dramatically increasing the world’s food supply without increasing crop production.

Business Description NanoGuard will license technology and sell cold plasma equipment, parts and services to the grain processing industry. The addressable market is over $ 1 Billion. The technology provides substantial supply chain benefits: Improved shelf life, Reduced risk of food-borne illness, Lower mycotoxins, Non-thermal process, More efficient than competing technologies

Core Technology/Products Grain is exposed in a machine that generates a high voltage cold plasma. As a gas is passed through the plasma generator section of the machine, it is ionized forming reactive gas species (RGS) that have antimicrobial properties. The gas is transported to another section of the machine where it contacts the grain decontaminating it. Once the gas is removed from the

high voltage field these RGS decay back to their native state leaving no residue.

Market Opportunities NanoGuard’s target market is in grain processing where FAO estimates that there are 1 billion metric ton of losses per year. We will license technology and sell cold plasma equipment, parts and services and target large grain processors (ADM, Bunge, Cargill, Dreyfus, Mars...) and integrators (Tyson, Pilgrims, Smithfield...) as our primary customer base. The market value alone for this sector exceeds $1 billion. The company will also probe several large adjacent markets; tree nuts and peanuts, fresh produce, meat and seafood, spices, brewing and seeds where market expansion could be easily achieved, addressable market $6 Billion.

Industry/Sector Postharvest Agriculture

Traction/Research Data Recently signed an exclusive licensing agreement with Bunge International in the grain market completing our A round funding.

1100 Corporate Square Drive, Suite 229, St. Louis, MO 63132

Page 23: nineteen startups

[email protected]

Competitive Advantage There are three competitive technologies used today; Thermal Treatment, Irradiation, and Chemical Treatment. Irradiation has had limited success in the industry because of public perception. Chemical treatments are used in only niche markets because of cost and residues left on the treated grain. Thermal treatments are the most prevalent technology used, but have undesired effects on the product’s characteristics after treatment. There are currently no technologies available that can address both the spoilage and mycotoxin issues in the market.

Current Investors Nidus Partnership, Monsanto, Bunge and the Yield Lab

Financials Nanoguard expects its first revenue in 2018 from royalties and the sale of several large systems.

Item 2016 2017 2018 2019 2020

Revenue $4,000 $16,000 $45,000

E x penses $1,500 $1,700 $4,200 $13,642 $33,451

Net Incom e $-960 $-1,088 $-128 $1,509 $7,391

Management Mark A. Hochwalt, President and CEO Mark is an entrepreneur and businessman with broad experience in the chemical, agricultural, water treatment, pharmaceutical and animal nutrition industries. He holds seven patents covering a range of technologies. He is a serial entrepreneur having founded three other businesses prior to becoming CEO of NanoGuard. Mark has a degree in Chemical Engineering from the University of Cincinnati.

Dr. Kevin Keener Founder and Technology Consultant Kevin is the inventor of the technology and an owner in the company. He is a recognized expert in this field. He is providing technical consulting for the design and scale up of the technology. Kevin has a PhD in Food Process Engineering from Purdue and is currently at Iowa State University.

Dr. Cherian George Regulatory Affairs Director Cherian was recently Monsanto’s Regulatory Affairs Manager where he was instrumental in gaining FDA GRAS approval for several genetically modified crop products. He has a PhD in Organic Chemistry from Loyola University of Chicago.

Item 2016 2017 2018 2019 2020

Revenue $4,000 $16,000 $45,000

E x penses $1,500 $1,700 $4,200 $13,642 $33,451

Net Incom e $-960 $-1,088 $-128 $1,509 $7,391

Item 2016 2017 2018 2019 2020

Revenue $4,000 $16,000 $45,000

E x penses $1,500 $1,700 $4,200 $13,642 $33,451

Net Incom e $-960 $-1,088 $-128 $1,509 $7,391

Item 2016 2017 2018 2019 2020

Revenue $4,000 $16,000 $45,000

E x penses $1,500 $1,700 $4,200 $13,642 $33,451

Net Incom e $-960 $-1,088 $-128 $1,509 $7,391

Item 2016 2017 2018 2019 2020

Revenue $4,000 $16,000 $45,000

E x penses $1,500 $1,700 $4,200 $13,642 $33,451

Net Incom e $-960 $-1,088 $-128 $1,509 $7,391

Page 24: nineteen startups

24

Value Proposition Current bacterial diagnostic tests take days; physicians therefore are regularly forced to prescribe antibiotics based on symptoms alone. This inefficient process has created an epidemic of antibiotic misuse that skyrockets healthcare costs $35B annually. Nanopore Diagnostics is developing rapid and point-of-care tests that will fight this misuse by ensuring physicians have definitive diagnostic information in-hand before needing to prescribe antibiotics.

Business Description Our primary offering will be a point-of-care testing device capable of diagnosing bacterial infections in 30-minutes. It will utilize consumable cartridges specific to certain types of infections. Our initial application will be the blood-borne infections of sepsis patients. Sepsis kills fast and requires immediate treatment. As sepsis diagnostic tests take days physicians administer antibiotics blindly and then move to more optimal treatments when test results return days later. Our test will instead diagnose in 30-minutes enabling physicians to administer optimal treatments upfront. This will save thousands per patient by decreasing mortality rates and the length of hospital stays.

Core Technology The underlying technology allowing for our rapid test is a nanopore sensor called the iNDxer. It directly counts RNA and DNA molecules specific to pathogenic organisms that might be present in a clinical sample. Just as a change-sorter can quickly count all the nickels in a change jar, the iNDxer can quickly scan for pathogen nucleic acids as a clinical sample is applied to the sensor. The iNDxer presents three primary competitive advantages: 1) Increased sensitivity allowing for testing without day-long culture procedures, 2) Ability to test in raw samples ensures a rapid and user-friendly test, add the whole sample directly to the device. and 3) The potential for portability allows for point-of-care testing.

Market Opportunities There are over 1.8 million sepsis diagnoses made in US hospitals annually. This puts the addressable opportunity for our consumable test at $310M if we price each cartridge at $169. Our device, priced at $22,000, will be sold separately. As our consumable assays can be quickly adapted to detect other microbe panels, the clinical microbiology market, estimated at $6 billion, is our ultimate target market.

4320 Forest Park Ave, Suite 304, St. Louis, MO 63108

Page 25: nineteen startups

[email protected] | www.nanoporedx.com

Industry/Sector Molecular Diagnostics/Biotechnology

Current Investors Missouri Technology Corporation, Arch Angels, Biogenerator, other Angels.

Traction / Research Data 4 grant competitions 1st place victories. Clinical validation of our platform is complete. 4 issued patents in the US and abroad, 7 more pending.

Management Tom Cohen, PhD, Co-Founder & CEO Dr. Cohen helped co-found Nanopore Diagnostics following 10 years working in genomic technology development in academic settings. He has previous startup founder experience in the non-profit world (The BALSA Foundation) and completed the Pipeline Entrepreneur Fellowship, a nationally recognized program focused on accelerating the growth of first-time entrepreneurs.

Christoph Bausch, PhD, MBA, Co-Founder Dr. Bausch has over 18 years of technical and business experience commercializing platform technologies within the life science industry. This includes microbiology research roles as well as business development positions for large biotech firms including Sigma Aldrich and POET Biofuels. He helped co-found Nanopore Diagnostics and is still actively involved serving on the board of directors and assisting with strategic direction.

Somes Das, PhD, Lead Scientist Dr. Das has a biophysical and chemical engineering background spanning academic professor and industrial senior scientist positions. He has a highly relevant knowledgebase for Nanopore Diagnostics having focused his career on nanopore-based technologies and their applications.

Financials The company does not publicly disclose detailed financial information but has raised $1M to date in seed funding and is about to launch a $3M Series A round.

Page 26: nineteen startups

26743 Spirit 40 Park Drive, Chesterfield, MO 63005

Value Proposition Most institutional investors who maintain a fixed income securities portfolio have built the portfolio on bias broker recommendations, bond brokers are inclined to sell investments that are in their best interests. Many institutional buyers will not pay for the very expensive tools for pricing, analytics, and risk analysis. We provide the “Kelly Blue Book” for the bond buyer. We price, analyze, and quantify the risks of every bond in the market. The buyer now has a tool to make better-informed decisions and has an internal control to protect their entity.

Business Description PFITR provides customers an online tool that helps institutional fixed income securities investors to make more informed decisions. We are a SaaS solution for the institutional buyer managing a bond portfolio.

Core Technology / Products Our Flagship product is called the Bond Price Validation® (BPV®) tool. It is an internal control that allows buyers to see the true fair market value (often much different than the original broker quote). the pricing history, treasury spreads, interest rate risk and many other analytics imperative to the fixed income securities buyer.

Market Opportunities Our focus is currently directed at Banks and Credit Unions with under 1 billion dollars in assets and medium sized local governments with over 25 Million dollars in assets. Brokers target these unsophisticated investors and sell them investments with large commissions and elevated market risk in a rising interest rate market. Regulators see the problem and are demanding internal controls and tools to help institutional investors with buying decisions.

Management Team Jim Koetting Founder and CEO, Todd Priest Systems Architect

Industry/Sector Financial Software, Analytics

Current investors VC Fintech, MTC, UMB Bank, Capital Innovators, SixThirty, DRK Investments, and Angel Investors

Page 27: nineteen startups

[email protected] | http://pfitr.com

Traction / Research Data Contracted to provide education for the Association of Public Treasurers of the United States and Canada, the CPFIM program and ACPFIM. Paying customers in 15 States.

Competitive Advantage We are the first low-cost solution that works as an internal control on purchasing fixed- income securities. PFITR leverages proprietary algorithms and analytics to help buyers make more cost-effective, responsible purchasing decisions.

Strategic Partners / Alliances FIS, The Association of Public Treasurers of the United States and Canada,

Management Jim Koetting Jim is one of the top thought leaders in public treasury management. Recognized as a trend-setter in the world of financial technology (Fintech), he has created ground-breaking software that meets the needs of public treasurers everywhere. As an accomplished author, he is well known among elected treasurers and sought after to professionally speak on many treasury management topics.

Todd Priest Over the course of his 20-year career, Todd Priest has both led and supported software engineering teams for financial powerhouses including Edwards Jones, MasterCard, A.G Edwards, and Thomson Reuters.

Financials The Company does not publicly disclose financial information. The company has raised $850,000 and is seeking 1.2 million in a late seed round.

Page 28: nineteen startups

28

Value Proposition The John Cunningham virus (JCV) is very common – more than 70% of adults have been exposed and possess serum antibodies – but in healthy individuals it is completely harmless. In patients undergoing immunomodulatory therapy, however, a particular strain of JCV can cause the highly lethal neurodegenerative condition Progressive Multifocal Leukoencephalopathy (PML). Because existing techniques are incapable of determining the strain of a JCV infection, immunomodulatory drug markets are severely restricted. We offer a blood test for virulent strains of JCV to increase patient access to therapeutics.

Business Description Pro-Arc Diagnostics is developing JCVerify, a novel qPCR assay that distinguishes variant forms of JCV. Current methods for assessing JCV risk in certain patient populations rely on an outdated understanding of the virus’ pathophysiology. As a result, hundreds of thousands of patients are denied access to highly effective immunomodulatory therapies. JCVerify will patient access and an expanded market for Biogen’s blockbuster MS drug Tysabri.Core Technology/Products: JCVerify is a multiplex quantitative PCR test that

quantifies virulent and non-virulent JCV, allowing accurate monitoring of PML risk in immunocompromised patients.

Market Opportunities Our first target market will be Multiple Sclerosis, with 400,000 patients in the United States. Our test is also relevant for other autoimmune diseases (Crohn’s Disease, Rheumatoid Arthritis, Psoriasis: 9.98M patients); blood cancers (Leukemia/Lymphoma: 1.2M); organ transplant recipients (30K); and HIV/AIDS (1.2M).

Industry/Sector Life Sciences/Diagnostics

Traction/Research Data The technology for JCVerify was invented at and patented by the National Institutes of Health, where over $20M in resources were spent developing the test. Published research has demonstrated the efficacy of our test in a small number of human patient samples.

4320 Forest Park Ave, Suite 303, St. Louis, MO 63108

Page 29: nineteen startups

[email protected] | www.pro-arcdx.com

Competitive Advantage Pro-Arc has obtained an exclusive license to the IP underlying our test. Because of the breakthrough technique underlying JCVerify, ours is the only assay on the market that can identify the virulent forms of JCV which pose a risk to immunocompromised patients.Strategic Partners/Alliances: Our company has a clinical research relationship with the MS treatment center at Washington University/Barnes Jewish Hospital and has access to lab space and equipment through BioGenerator in St. Louis.

Current Investors nCourage Entrepreneurs

Financials Pro-Arc Diagnostics is preparing to raise seed investment.

ManagementMichelle Faits, CEO She has her PhD in Developmental, Regenerative, and Stem Cell Biology from Washington University and is a 2016 Pipeline Entrepreneurs fellow.

Dana Watt, CSO She has her PhD in Neuroscience from Washington University and is a Postdoctoral fellow in Innovation and Entrepreneurship at WashU.

James Sorrell, CFO A former neurology researcher and biotechnology consultant and is currently a venture analyst at the Skandalaris Center for Entrepreneurial Studies.

Page 30: nineteen startups

30

Value Proposition Clinical stage company testing Magnetically Enhanced Diffusion (MED) in an acute ischemic stroke population. Significant funding recently captured in a series B round.Business Description: Pulse is a clinical stage medical device company pioneering MED or Magnetically Enhanced Diffusion. While a platform drug delivery technology, the company is scheduled to start a clinical trial in November of 2016

Core Technology/Products MED Workstation and MED MicroBeads. The MED Workstation consists of a small, portable, motorized spinning magnet that preferentially directs intravenously delivered nanoscale iron oxide MED MicroBeads to the target of a clot.

Market Opportunities Multiple billion dollar opportunity

Industry/Sector Medical Device

Traction/Research DataFirst In Human evaluation completed. FDA IDE approval received.

Competitive Advantage Scalable to any hospital that treats stroke with techniques ranging from drug delivery to cath lab comprehensive centers

Strategic Partners/Alliances Multiple venture investors involved through A and B rounds

Current Investors NanoDimension, OSF Ventures, FTL Capital, BioGenerator, Cultivation Capital, Angel networks, etcFinancials: Company has funding structure through 2017 and enough to cover trial costs and CE approvals

ManagementSean Morris, CEO Founder of Veniti Medical, GM at AngioDynamics

Francis “Duke” Creighton Ph.D., CTOKay Broschat, Ph.D., Director of Clinical Research

Denny Moore Ph.D., Director of Chemistry

Brian Kidd MSE, VP of Engineering

911 Washington Ave, Suite 730, St. Louis, MO 63101

Page 31: nineteen startups

[email protected] | www.pulsetherapeutics.com

Page 32: nineteen startups

321520 S. Vandeventer Ave, St. Louis, MO 63110

Value Proposition We enable software vendors to brand and resell integration plugins that meet the need of more than 80% of their client base, markedly reducing cost to develop and time to market while increasing engagement and expanding revenue by as much as 40%.

Business Description Ryvit was founded on one fundamental observation: businesses are demanding an integrated application experience to enable workflow and analysis. Coupled with this imperative, software companies are failing as they lack the focus and resources needed to rapidly develop and deploy integration solutions to their customer base. Recognizing this gap led to the creation of the Ryvit platform, delivered as a service through a partner-focused channel.

Core Technology/Products Integration Platform-as-a-Service that focuses on Accounting/ERP systems for integration targets for all of the software vendors that can benefit from that type of inter-application interaction. We are built on the .Net stack, leveraging the Microsoft Azure platform.

Market Opportunities Approx 9,000 software vendors operating just in the United States, with a combined customer base of over 23 million that can be targeted for potential subscriptions.

Industry/Sector Technology / Software sector.

Traction/Research Data Product-ready and generating revenue. We have an initial focus within the Architecture, Engineering, and Construction industries to achieve disruption and expand into other verticals. We currently have 7 active partners, including one of the top 3 Accounting/ERP software vendors in the ACE industry at large, with more than 30 prospective customers in the pipeline positioned to close.

Competitive Advantage We are competing in two key ways. 1) Every other iPaaS has a generic approach in which they simply provide tools for vendors or end users to establish integration. We are pre-building the solution, based on defined workflow on the basis of industry-focused best practices. 2) We have a very deep focus within the industry in terms of truly understanding, identifying, and then building solutions based on defined workflows in the industry.

Page 33: nineteen startups

[email protected] | http://ryvit.com/

Strategic Partners/Alliances Dexter+Chaney, a top 3 ERP/Accounting software vendor in the AEC industry. Buildingblok, a software application under the BlueBook umbrella with access to over 30,000 customers.

Current Investors Professionals Venture Fund out of Indianapolis, IN, Friends and Family

Financials Ryvit has raised almost $1MM to fund startup and will seek an additional round in 2017. Annual Recurring Revenue is approaching the breakeven point based on current operating costs.

Management Team BiosTom Stemm, CEOOver 15 years of experience building companies and working in the software development area of technology.

Nick Smarellie, FounderOver 15 years of experience working within and leading sales and marketing teams, including many years of experience in the Fortune 100 space.

Joe Gadell, FounderOver 20 years of experience working with technology and architecting solutions across many variable technology stacks.

Page 34: nineteen startups

34

Value PropositionReduce readmissions

Provide caregivers a tool to help them intervene early for improved outcomes

The system automatically identifies the patients who need the most help, allowing caregivers to optimize their existing resources

Increases patient satisfaction

Reduces lost patient revenue

Business Description SanusEO is a rapidly deployable cloud-based patient engagement platform that utilizes text messaging to connect patients and caregivers. We narrowly focus on specific disease sets (diabetes, congestive heart failure, knee and hip joint replacement and COPD) with a concentration on outcome improvement and patient satisfaction for transitional care. Core Technology/Products SanusEO’s platform and HIPAA-secure web portal is written in php with a MySQL database. All data in the database is encrypted at 256-bit encryption key. Text messaging is encrypted using TLS 1.2. Hosting is with Armor, a HITRUST certified vendor.

Market Opportunities The implementation of the Affordable Care Act in 2010 forever changed healthcare. More users of healthcare and an aging population are putting pressure on the delivery system. Meanwhile, regulatory changes like readmission penalties and an evolution toward bundled payments or shared risk/shared savings reimbursement models are driving the need for more efficient engagement with patients. Many software or app-based patient engagement platforms are very complex, expensive and difficult to implement. SanusEO’s text messaging platform utilizes a common, effective, everyday means of communication. Industry/Sector Healthcare services

Traction/Research Data SanusEO has one payer customer and a handful of hospitals. The current plan is focused on targeting providers and payers while starting to explore self-insured companies and corporate wellness programs. The current pipeline consists of $400K of revenue in various stages.

SanusEO had the following results in our early pilots. The data was

911 Washington Ave., Suite 721, St. Louis, MO 63101

Page 35: nineteen startups

[email protected] | www.sanuseo.com

independently analyzed by St. Louis University Center for Outcomes Research.

57% reduction in readmissions65% response rate80% completion rate93% of participants said the

program was “very helpful.”Our insurance company customer’s actuary projected an 8:1 return on investment.

Competitive Advantage SanusEO’s cloud based text messaging platform reaches the entire 90% of the population who has a cell phone, including the 42% who don’t own a smart phone. We can implement our platform in less than 30 days and have actionable data 30 days later.

Strategic Partners/Alliances We have a letter agreement with a consulting firm to expand into the self-insured world. We have begun talks with a very large independent rep distribution group to help scale our direct to provider sales approach. Two strategic partners are evaluating our solution to include it in their suites of provider solutions.

Current Investors angels, Missouri Technology Corporation, St. Louis Tech Fund, Prosper, Biogenerator, St. Louis County Port Authority

Financials Goal is to get to $600K closed by the end of the year. Capitalized with over $750K. Missouri Technology Corporation is investing for the second time, $75K. SanusEO is raising an additional $250K in equity. A larger equity raise is to occur in 2017.

ManagementMatt Fagin, CEO 25 year career in finance with a 14 year start in commercial banking. History of investing, mentoring, advising and operating a variety of entrepreneurial concerns. Matt is a principal in Detalus Consulting who provides additional backup support to SanusEO in the following areas: sales, finance, operations, marketing and technology.

Dana Fowler, Founder & Chief Innovation Officer Dana is a successful entrepreneur in the digital marketing space. She pioneered consumer-based mobile application development solutions for Fortune 500 companies.

Page 36: nineteen startups

36

Value Proposition Soozie’s Doozies is the creator of the first and only pre-cut refrigerated cookie dough in a stand up pouch and has achieved patent pending status on this revolutionary innovation. Soozie’s Doozies refrigerated cookie dough is all natural, non-GMO, and allows consumers to make the country’s greatest tasting cookies at home. Move over break ‘n bake cookie dough-- this pouch is more convenient for cookie lovers to open, store, and use. The added pouch window gives a fresh appearance and instantly conveys the tastiness that awaits inside this new packaging format. Business Description Soozie’s Doozies is the next “must have” baking brand known for its purity, convenience, and homemade taste. Baked goods is a $10 Billion+ category and Soozie’s Doozies is starting by entering the $500 million refrigerated cookie dough category. The refrigerated cookie dough category is in the dairy case which is the most highly trafficked area in the grocery store as all consumers purchase milk. We are building brand awareness in the dairy section and then will move to other grocery categories in 3+ years. Our goal is to be the next $100 million+ baking brand.

Core Technology / Products We invented the first ever, pre-cut refrigerated cookie dough in a stand up pouch. We use a proprietary cookie dough process to form the cookie dough pieces that our COO developed. We manufacture this product ourselves in our 16,000 square foot facility in the greater St. Louis area. This facility is able to meet our planned high growth trajectory over the next 5 years.

Market Opportunities Our refrigerated cookie dough pouches solves 3 unmet consumer needs in the refrigerated cookie dough category: 1. All natural, refrigerated cookie dough that makes great tasting cookies; 2. Refrigerated cookie dough that is more convenient; 3. Refrigerated cookie dough that offers transparency. Industry/Sector Consumer Products, Food & Beverage Current investors Prosper Women Entrepreneurs

12 Cedar Ct., Union, MO 63084

Page 37: nineteen startups

37

Traction / Research Data The pouches were introduced in the Midwest region in September 2015 and in 12 short months expanded to the East Coast and Southwest, with a total presence in 800+ retail grocery stores.

Competition / Competitive Advantage Patent Pending Formula. Proprietary Cookie Dough Forming Process. First to market advantage. Contracts with retailers. Soozie’s Doozies anticipates growth in retail from 800+ locations to many more in 2016.

Strategic Partners / Alliances Soozie’s Doozies partners with local, regional and national distributors to support its growth. Our national/regional distributors include: UNFI, Kehe, AWG, and Hautly.

ManagementOlivia Kelvin, CEO BSc. Food Scientist, 15+ years in food product research and development at Sara Lee, Hillshire Brands, and English Bay Batter.

Bob Stanton, COO MSc. Engineering, 30+ Years of experience in food manufacturing and R&D including Kelloggs, Anheuser Busch, and Sara Lee.

Financials The company has bootstrapped the business to date and is actively seeking investors for a Series A round to finance their high growth.

[email protected] | www.sooziesdoozies.com

Page 38: nineteen startups

38

Value Proposition Sparo Labs’ flagship product, Wing® helps people achieve and maintain asthma control to improve quality of life and reduce asthma attacks, ER visits, and hospitalizations.

Business Description Sparo Labs is an award-winning, digital health startup committed to transforming respiratory care for patients—from reactive to proactive. Wing® is the first FDA-cleared, over-the-counter smartphone sensor for measuring lung function. Wing empowers people to control their asthma or other respiratory condition with a powerful app and pocket-sized sensor that measures lung function with medical-grade accuracy and helps patients manage their medications, triggers, and symptoms.

Core Technology/Products Wing’s underlying technology combines a novel and patent-pending acoustic sensor with proprietary signal processing algorithms to reduce cost and complexity, which have previously limited patient access to spirometry. Wing was designed to help people with asthma manage their condition on a daily basis. With Wing, users can measure and track lung function to detect early warning signs and take

the right medication at the right time to prevent asthma flare-ups. Users can also work with their care team to identify and avoid things that trigger their asthma and evaluate whether their medication regimen needs to be adjusted. With Wing’s cloud-based platform, Sparo Labs is building the largest source of aggregated data on respiratory diseases ever assembled. This holds tremendous potential for illuminating how patients respond to their environments and medications on both an individual and macro scale.

Market Opportunities Over 30 million people have asthma in the U.S. (300-400 million worldwide). Asthma is the #1 condition causing ER visits, hospitalizations, and missed school for children. Of the people with asthma in the U.S., approximately 60% have uncontrolled, persistent asthma or a total of 18 million people that struggle to breathe on a daily basis and are at a high risk for a significant asthma attack.

Industry/Sector Healthcare/Digital Health

911 Washington Ave., Suite 809, St. Louis, MO 63101

Page 39: nineteen startups

39

Traction/Research Data Sparo Labs is working with collaborators at Washington University in St. Louis Medical School on an initial asthma pilot with Wing. Sparo Labs has built a community of 12,000+ people excited about Wing. In Fall 2015, Wing raised $50,000 in contributions from 400+ patients in 30 days, serving as a recruitment pool for pre-FDA beta & UX studies.

Competitive Advantage• First mover advantage• Organic, patient-facing brand• Strong relationships with leaders

in healthcare• Proprietary technologies

Strategic Partners/Alliances Sparo Labs is in the process of formalizing partnerships with several pharmaceutical companies and pharmacy benefit managers.

Current Investors Angel Investors and Family Offices in Missouri, Michigan, San Diego, and New York.

Financials Sparo Labs has raised $2.7M in total grants and investment since founded in October 2012. Sparo Labs plans to raise a $4m Series A round of funding.

Management Sparo Labs is led by co-CEOs, Andrew Brimer and Abby Cohen, who founded the company in 2012 while studying engineering at Washington University in St. Louis. Abby and Andrew began working full-time at Sparo Labs in 2013. Sparo Labs has won 10 of 12 competitions resulting in $275,000 in grant funding from organizations including the NIH and IEEE. In Fall 2015, Sparo Labs was invited to present at the first ever White House Demo Day.

[email protected] | www.mywing.io

Page 40: nineteen startups

40

Value Proposition Tunespeak is a loyalty platform for the music industry. Our mission is to help artists identify and reward their most passionate fans.

Business Description Tunespeak provides the following products: (1) consumer website on which fans can earn points for consuming and sharing music content towards giveaways & (2) client website on which artists can connect directly with top fans.

Market Opportunities There are thousands of touring artists and millions of music fans across the globe. Tunespeak aims to to be the loyalty platform for the music industry.

Management Tom Pernikoff, CEO & Co-Founder

Industry/Sector Music / Tech

Current investors Cultivation Capital, St. Louis

Traction / Research Data Tunespeak has engaged millions of music fans and served some of the biggest artists in the industry including Maroon 5, Kendrick Lamar,

Dave Matthews Band, Wilco, Miranda Lambert, Linkin Park, Brian Wilson, KISS, Fifth Harmony, My Morning Jacket, Guns N’ Roses, John Mayer, Selena Gomez, Kings Of Leon, Dr. Dre, Blake Shelton, Leon Bridges, Aerosmith and many more.

Competitive Advantage Tunespeak has competitors in the space (Tweetmatic, ToneDen, FanFueled) but none of them serve the volume of clients that Tunespeak does. Tunespeak’s technical solution more effectively solves an industry-wide engagement problem.

Strategic Partners / Alliances Tunespeak partners with renown artists, management companies, talent agencies, record labels, ticketing companies and streaming services. Management Tom Pernikoff Tom is the CEO and Co-Founder at Tunespeak. Before Tunespeak, he toured as the lead singer and guitarist of the band, Pernikoff Brothers. He was also on the founding team of Silicon Valley startup, Loopt. Tom holds degrees in Economics and Music from Brandeis University.

911 Washington Ave., St. Louis, MO 63101

Page 41: nineteen startups

41

Financials Tunespeak does not publicly disclose financial information. Tunespeak has raised more than $3 million since its founding.

[email protected] | www.tunespeak.com

Page 42: nineteen startups

42

NOTES

Page 43: nineteen startups

43

NOTES

Page 44: nineteen startups

44

• “Top 10 Large American Cities of the Future” … FDI Magazine

• “Top 7 U.S. Innovation Districts” … Brookings Institute

• “Best Startup City in America” ... Popular Mechanics

• “One of the Best Cities for College Graduates” … Career Bliss

• “Top 10 City for Recreation” … Wallethub

• “Top 10 Affordable Cities” … Forbes

• “Hidden Gem City” … Huff Post Travel

• “Fastest Growing City for Tech Jobs” … Fortune

• “Top 12 Cities for Jobs” … Glassdoor.com

• “10 Most Creative Cities” … Movoto.com

• “#1 City Park” … USA Today

• “Top Sports City in America” … Wall Street Journal

• “Top 25 Music Cities” … Travel & Leisure

• “Top Place to Visit in the World” … New York Times

• “#6 Best U.S. City for Staycations” … Wallethub

• “One of America’s 20 Most Popular Places to Visit” … Trip Advisor

for startups!